SWP
AST

Stratos Wealth Partners’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Stratos Wealth Partners’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-33
Closed – – 3070
2018
Q3 		$0 Buy
+33
New +$51 ﹤0.01% 3107
2018
Q2 		– Sell
-33
Closed – – 3181
2018
Q1 		$0 Sell
33
-3
-8% -$6 ﹤0.01% 3343
2017
Q4 		$0 Buy
+36
New +$91 ﹤0.01% 2880

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stratos Wealth Partners's AST Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 33 shares.

Stratos Wealth Partners first reported a position in AST in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 33 Asterias Biotherapeutics Inc. Series A shares in Q4 2018.
  • Stratos Wealth Partners first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q3 2018.
  • 46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.